10.1080/19490976.2023.2274124 109 WangW.MeiA.QianH.LiD.XuH.ChenJ.et al (2023b)
Some are now FDA-approved for chronic weight management, including semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound), and liraglutide 3 mg (Saxenda)
For weight management, inadequate response (less than 5% weight loss after several months at maintenance dose) may warrant reassessment of the treatment approach
See all FAQs Important safety information and common side effects GLP-1 medications should be used with a reduced-calorie meal plan and increased physical activity
A high prevalence of TD has been reported among both type 1 DM (T1DM) and type 2 DM (T2DM) patients ( GLP-1 is an amino acid peptide hormone secreted by L cells of the gastrointestinal mucosa that promotes insulin secretion, suppresses glucagon secretion, and delays gastric emptying ( GLP-1 receptor agonists, a new type of antidiabetic drug for treating T2DM in recent years, with additional benefits of weight loss and blood pressure reduction ( Methods Data Sources and Searches We searched PubMed (MEDLINE), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible RCTs without restriction of language or publication period
